116 related articles for article (PubMed ID: 1124151)
1. [Clinico-prognostic significance of plasma cortisol half-life(after intravenous administration ) during acute and chronic hepatic diseases].
Del Prete S; Malacco E; Bonzi G; Natelli A; Roncoroni S; Jalanbo H
Minerva Med; 1975 Mar; 66(22):1051-7. PubMed ID: 1124151
[TBL] [Abstract][Full Text] [Related]
2. The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
Klotz U; Avant GR; Hoyumpa A; Schenker S; Wilkinson GR
J Clin Invest; 1975 Feb; 55(2):347-59. PubMed ID: 1127104
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of theophylline in patients with liver diseases.
Staib AH; Schuppan D; Lissner R; Zilly W; von Bomhard G; Richter E
Int J Clin Pharmacol Ther Toxicol; 1980 Nov; 18(11):500-2. PubMed ID: 7203726
[TBL] [Abstract][Full Text] [Related]
4. [Significance of the study of bile salts in acute and chronic liver disease].
D'Aquino M; Della Sala S; Fazzin G; Michieletto L; Saonato F
Quad Sclavo Diagn; 1987 Jun; 23(2):132-6. PubMed ID: 3451290
[TBL] [Abstract][Full Text] [Related]
5. [Hepatic and renal elimation of bromsulphalein in chronic hepatitis, post-inflammatory cirrhosis and obstructive jaundice].
Babiuch L
Przegl Epidemiol; 1975; 29(2):159-67. PubMed ID: 1144806
[No Abstract] [Full Text] [Related]
6. [Hepatic clearance of 99mTc-p-butyl HIDA in liver diseases. Correlations with routine hematochemical parameters of liver function].
Custro N; De Francisci MC; Patanella I; Scafidi V; Indovina I
Minerva Med; 1984 Nov; 75(42):2527-32. PubMed ID: 6083507
[TBL] [Abstract][Full Text] [Related]
7. [Aspects of cortisol metabolism in liver diseases].
Della Casa L; Boni M
Endocrinol Sci Cost; 1967 Nov; 29(5):344-53. PubMed ID: 5616116
[No Abstract] [Full Text] [Related]
8. Impaired elimination of meperidine in patients with liver disease.
McHorse TS; Klotz U; Wilkinson G; Schenker S
Trans Assoc Am Physicians; 1974; 87():281-7. PubMed ID: 4456737
[No Abstract] [Full Text] [Related]
9. The daily rhythm of cortisolemia in hepatic cirrhosis.
Ruzyllo E; Dzieniszewski J; Milewski B; Krygier T
Mater Med Pol; 1973; 5(1):9-16. PubMed ID: 4774849
[No Abstract] [Full Text] [Related]
10. Drug disposition in liver disease.
Fruncillo RJ
Am Fam Physician; 1982 Dec; 26(6):167-9. PubMed ID: 7148640
[No Abstract] [Full Text] [Related]
11. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
12. [Metabolism of phenylbutazone in the liver (author's transl)].
González Macías J; De Castro del Pozo S
Med Klin; 1976 Sep; 71(36):1434-8. PubMed ID: 958107
[TBL] [Abstract][Full Text] [Related]
13. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease.
Wittayalertpanya S; Israsena S; Thamaree S; Tongnopnoua P; Komolmit P
Tokai J Exp Clin Med; 1996 Dec; 21(4-6):195-201. PubMed ID: 9300980
[TBL] [Abstract][Full Text] [Related]
14. [Aminophenazone half life in patients with chronic liver parenchyma disorders].
Ackermann E; Renger F; Dökert B; Walther M
Z Gesamte Inn Med; 1972 Oct; 27(19):849-53. PubMed ID: 4647370
[No Abstract] [Full Text] [Related]
15. [Pharmacokinetics of thiamphenicol. Behavior in a acute and chronic hepatic insufficiency].
Menz HP; Bezler HJ; Hartmann I; von Oldershausen HF
Arzneimittelforschung; 1974 Jan; 24(1):99-102. PubMed ID: 4406121
[No Abstract] [Full Text] [Related]
16. [Diagnostic value of the study of caffeine elimination in chronic liver diseases].
Darnót G; Nemesánszky E; Bariska J
Orv Hetil; 1995 Apr; 136(18):927-32. PubMed ID: 7739851
[TBL] [Abstract][Full Text] [Related]
17. [Determination of serum procollagen-III peptide in chronic liver diseases. Clinical usefulness].
Pagani A; Zigliani P; Pranzo A; Galante T
Minerva Med; 1992 Nov; 83(11):715-20. PubMed ID: 1461542
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine metabolism in patients with liver disease.
Levine RJ; Conn HO
J Clin Invest; 1967 Dec; 46(12):2012-20. PubMed ID: 6074004
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of famotidine after intravenous administration in liver disease.
Ohnishi K
Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
[TBL] [Abstract][Full Text] [Related]
20. [Studies on bilirubin glucuronide. I. A study on the relation of bilirubin glucuronide in bile and liver damage].
Takagi M
Igaku Kenkyu; 1969 Jun; 39(3):255-64. PubMed ID: 5389947
[No Abstract] [Full Text] [Related]
[Next] [New Search]
